Emerging Infectious Disease Tests and Companies Developing New Technologies and Products

Date: September 22, 2011
Pages: 650
Price:
US$ 3,850.00 US$ 3,272.50
License [?]:
Publisher: VPGMarketResearch.com
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C5E023D2CCBEN
Leaflet:

Download PDF Leaflet

Emerging Infectious Disease Tests and Companies Developing New Technologies and Products
The report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects for nearly 80 infectious diseases and viruses, including their scientific background, clinical significance and market needs for both current and emerging tests, vaccines, drugs and extensive listings of companies developing or marketing new technologies and products.

Contains 650 pages and 47 tables
1. AIDS

a. Background
  Structure and Composition
  Classification
  Origin of AIDS
  Animal Lentivirus Systems
  Virus Receptos
  HIV Infections in Humans
  Pathogenesis & Pathology: Overview of HIV Infection Course
  CD4T Lymphocytes and Memory Cells
  Monocytes and Macrophages
  Lymphoid Organs
  Neural Cells
  Viral Coinfections
  Clinical Findings
  Plasma Viral Load
  Pediatric AIDS
  Neurologic Disease
  Opportunistic Infections
  Cancer
  Immunity
  Virus Isolation
  Serology
  Detection of Viral Nucleic Acid and Antigens
  Infectivity
  Epidemiology
  Worldwide Spread of AIDS
  United States
  Routes of Transmission
b. Diagnostic Tests
  Laboratory Diagnosis
  Enzyme Immunoassay Interpretation
  Specific, Sensitivity, and Predictive Value of Enzyme Immunoassays
  Competition Assays
  Western Blot Technique
  Immuno-Fluorescence Assay (IFA)
  Radioimmunoprecipitation
  HIV-1/HIV-2 Combination Testing
  Methods of HIV-Antigen Detection
  Antigen Assays and Blood Screening
  Urine Tests
  Immunopathogenic Mechanism of HIV Infection
  DNA Probes
  Overview
  Quantitative Polymerase Chain Reaction
  In Situ PCR
  Needed Improvements
  Viral Load/Drug Resistance Testing
  Genotype and Phenotype Testing
  Blood Banking Consideration
c. Vaccines and Drugs
  Antiviral Drugs
  Vaccines Against HIV
  Transmission of HIV in Blood Products
  HIV Transmission in Transplant and Artificial Insemination Recipients

2. ADENOVIRUS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
d. Adeno-Associated Viruses(AAV)

3. AEROMONAS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

4. ANTHRAX/BACILLUS ANTHRACIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

5. ARBOVIRUSES

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

6. BABESIOSIS

a. Background

7. BACILLARY EPITHELIOID ANGIOMATOSIS (BEA) AND OTHER BARTONELLA (ROCHALIMAEA)

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

8. BLASTOCYSTIS HOMINIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

9. BRUCELLA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

10. CAMPYLOBACTER

a. Background
b. Diagnostic Tests
Identification from Culture
c. Vaccines and Drugs

11. CANDIDA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

12. CHAGAS DISEASE

a. Background

13. CHANCROID

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

14. CHLAMYDIA

a. Background
  Chlamydia Psittaci
  Chlamydia Pneumoniae
  Chlamydia Trachomatis
b. Diagnostic Tests
c. Vaccines and Drugs

15. CLOSTRIDIUM DIFFICILE

a. Background
  Pediatric Infections
  Epidemiology
b. Diagnostic Tests
  Counterimmunoelectrophoresis
  Fluorescent-Antibody Assays
  Poloymerase Chain Reactions
c. Drugs and Vaccines

16. CORONAVIRUSES

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

17. COXSACKIEVIRUSES

a. Background
  Herpangina
  Hand-foot-and-mouth syndrome
  Hepidemic Conjuctivitis
  Pharingitis
  Epidemic Pleurodynia
  Myodarditis,Pericarditis
  Overwhelming Infection of the Newborn
  Acute Aseptic Meningitis
  Undifferentiated Febrile Illness
  Fever with upper respiratory infection
  Encephalitis
  Asymptomatic Infection
b. Diagnostic Tests
c. Vaccines and Drugs

18. CREUTZFELDT-JAKOB’S DISEASE

a. Background
  Blood Transmission
b. Diagnostic Tests
  Major Commercial and Academic Players
  Bayer
  Disease Sciences/Bio Tec Global
  Imperial College of Medicine
  Ortho-Clinical Diagnostics
  Pall
  ProMetic Life Sciences
  Proteome Sciences/Idexx
  Q-One Biotech
  Serono
  U.S. Agricultural Research Service
c. Vaccines

19. CRYPTOSPORIDIUM PARVUM

a. Background
b. Diagnostic Tests
  Histologic
  Laboratory Parasitology
  Serodiagnosis
c. Vaccines and Drugs

20. CYCLOSPORA CAYETANENSIS

a. Background
  Asymptomatic Infection
  Diarrhea in Immunocompetent Persons
  Diarrhea in Immunocompromisedersons
b. Diagnostic Tests
c. Vaccines and Drugs

21. CYTOMEGALOVIRUS

a. Background
  Chorioretinitis
  Gastrointestinal
  Central Nervous System Disease
b. Diagnostic Tests
c. Vaccines and Drugs

22. EBOLA VIRUS

a. Background
  Epidemiology
  Hemorrhagic Fever
b. Diagnostic Tests
c. Vaccines and Drugs

23. E. COLI

a. Background
  Role of Escherichia Coli in Causing Diarrhea
  EPEC
  ETEC
  EIEC
  EHEC
b. Diagnostic Tests
c. Vaccines and Drugs

24. ECHOVIRUS

a. Background
  Acute Aseptic Miningitisis
  Encephalitis
  Exanthems
  Respiratory Disease
  Myope;ricarditis
  Neonatal Infections
b. Diagnostic Tests
c. Vaccines and Drugs

25. ENCEPHALITIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

26. ENTEROVIRUSES

a. Background
b. Diagnostic Tests
  Viral Isolation and Identification
  Antibody Tests
c. Vaccines and Drugs

27. EPSTEIN-BARR VIRUS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

28. GIARDIA LAMBLIA

a. Background
  Life Cycle and Morphology
  Morphology of Trophozoites
  Clinical Disease
b. Diagnostic Tests
c. Vaccines and Drugs

29. GONORRHEA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

30. GRANULOMA INGUINALE

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

31. HANTAVIRUS

a. Background
  Identification of the Agent
  Transmission
  Other Rodent Hantaviruses
  Distribution
  Hantavirus Diseases
  Epidemiology
  Addendum in Proof-Northeastern Connection
  Previously Unknown Pathogens
  Cases Nationwide
b. Diagnostic Tests
  An Immunohistochemistry Approach
  Hantavirus Rapid Diagnostic Test
  ELISA Diagnosis of Hantavirus Pulmonary Syndrome
  IgG ELISA
  IgM Capture ELISA
c. Vaccines and Drugs

32. HELICOBACTER PYLORI

a. Background
  Pathogenesis
  Role in Peptic Ulcer Disease
  Role in Gastric Cancer
  Nonulcer Dyspepsia
b. Diagnostic Tests
c. Vaccines and Drugs
  Specific Therapeutic Regimens
  Who Should Be Treated?
  Participants in Controlled Clinical Trials
  Patients with Refractory Peptic Ulcer
  Patients with Refractory NUD
  Patients in High-Risk Groups for Gastric Cancer

33. HEPATITIS

a. Background
b. Hepatitis A
c. Hepatitis B
d. Hepatitis C
  Classification
  Transmission of Infection
  Occupational Hazards
  Acute Hepatitis
  Diagnosis of Acute Infection
  Chronic Hepatitis
  HCV and Other Chronic Liver Diseases
  Alcoholic Liver Disease
  Hepatitis B Coinfection
  Cirrhosis and Hepatocellular Carcinoma
  Diagnostic Tests
  Possible Indications for HCV RNA Testing
  Conclusions and Future Direction
e. Hepatitis D
  Historical Perspective
  Epidemiology
  HBV-HDV ""Coinfection"" vs. ""Superinfection""
  Methods of Detecting HDV
  Prevention
f. Hepatitis E
  Background
  Prevalence of the Disease
  Diagnostic Tests
  Epidemiologic Serosurveys
  Serologic Cross-Reactivity
g. Hepatitis G
  Vaccines and Drugs

34. HERPES SIMPLEX VIRUS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

35. HUMAN HERPES VIRUS-6 (HHV-6)

a. Background
  HIV-6 Infections
b. Diagnostic Tests
c. Vaccines and Drugs

36. INFLUENZA VIRUSES

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

37. LEGIONELLA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

38. LYME DISEASE

a. Background
Clinical Description
Clinical Case Definition
Laboratory Criteria for Diagnosis
Case Classification
b. Diagnostic Tests
c. Vaccines and Drugs

39. LYMPHOGRANULOMA VENEREUM (LGV)

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

40. MALARIA

a. Background
b. Diagnostic Tests
  Potential Diagnositic Problems with Positive Patients from Non-endemic Areas
  Patient
  Laboratory
  Physician
c. Vaccines and Drugs

41. MEASLES (RUBEOLA)

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

42. MENINGITIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
  Development of Polysaccharide Vaccines
  Quadrivalent Vaccine Development
  Meningococcal A.C.Y. & W-135 Vaccines
  Efficacy of Group C Vaccine
  Efficacy of Group A Vaccine
  Combinations of Group A and C Vaccines
  Group B Efficacy Trials
  Future Direction

43. MICROSPORIDIUM

a. Background
  Prevalence and Geographic Distribution
  Sources of Human Infection and Transmission
b. Diagnostic Tests
  Light Microscopic Examination of Stool Specimens By Chromotrope Staining
  Stool Concentration Methods
  Chemofluorescent Agents
  Giemsa Staining of Stool Specimens
  Cytologic Diagnosis
  Histologic Examination
  Electron Microscopy
  Examination of Bodily Fluids
  Examination of Tissue Sections
  Immunofluorescence Detection Procedures
  Serology
  Cell Culture
  Approach to Diagnosis
  Evaluation of Patients with Presumptive Intestinal Microsporidiosis
  Evaluation of Patients with Presumptive Ocular Microsporidiosis
c. Vaccines and Drugs

44. MONONUCLEOSIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

45. MUMPS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
  Efficacy of Vaccination
  Future Issues

46. MYCOPLASMA

a. Background
  Ureaplasma Urealyticum & Mycoplasma Hominis
b. Diagnostic Tests
c. Vaccines and Drugs

47. PAPILLOMAVIRUSES

a. Background
  HPV in Cancer
  Cervical Neoplasm
b. Diagnostic Tests
c. Vaccines and Drugs
  Prevention

48. PARVOVIRUS B19

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

49. PNEUMONIA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

50. POLYOMAVIRUSES

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

51. PSEUDOMONAS AERUGINOSA

a. Background
  Virulence Factors
b. Diagnostic Tests
c. Vaccines and Drugs

52. RABIES

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

53. RESPIRATORY SYNCYTIAL VIRUS (RSV)

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

54. RHINOVIRUSES

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

55. ROTAVIRUS (REOVIRUS)

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

56. RUBELLA(MEASLES)

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
  Developing Countries
  Elimination and Eradication of Measles
  New Developments

57. SALMONELLOSIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

58. SEPTICEMIA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

59. SHIGELLOSIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

60. STAPHYLOCOCCUS AUREUS

a. Background
  The Genus Taphylococcus
b. Diagnostic Tests
c. Vaccines and Drugs
  Prevention

61. STREPTOCOCCI

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
  Group A Streptococci
  Group B Streptococci

62. SYPHILIS

a. Background
b. Diagnostic Tests
  Biopsy
  Rabbit Infectivity Testing
  Other Diagnostic Modalities
c. Vaccines and Drugs
  Syphilis and HIV Infection
  Syphilis As a Cofactor for HIV Transmission
  Basic Science Issues

63. TOXOPLASMOSIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

64. TRICHOMONAS VAGINALIS

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

65. TUBERCULOSIS

a. Background
b. Diagnostic Tests
  Microscopic Characteristics
  Cultural Characteristics
  Detection of Antibodies
  Skin Tests
  MDRTB
c. Vaccines and Drugs

66. VIBRIO

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs

67. WEST NILE VIRUS

a. Background
  Clinical Syndromes
b. Diagnostic Tests
c. Vaccines and Drugs

68. YERSINA

a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
Skip to top


Ask Your Question

Emerging Infectious Disease Tests and Companies Developing New Technologies and Products
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: